Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beijing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| IGRA test for latent TB infection now available through the Stop TB Partnership’s Global Drug Facility | 0 | 303 | December 5, 2019 | |
| Fourth generation QuantiFERON-TB Gold-Plus: What is the evidence? | 0 | 415 | June 4, 2020 | |
| Performance of novel skin-based in-vivo tests for TB infection compared with PPD & IGRAs | 0 | 239 | October 2, 2021 | |
| WHO updates policy on Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV | 0 | 561 | November 4, 2019 | |
| Generating high-quality evidence for policy on WHO high-priority target product profiles for TB diagnostics | 2 | 766 | October 16, 2019 |